Skip to content

Optimization of the Parameters of Vagal Nerve Stimulation

Optimization of the Parameters of Vagal Nerve Stimulation in Pharmaco- Resistant Epileptic Patients Based on a Surface EEG Index of Functional Connectivity (PLI: Phase Lag Index): a Randomized Double-blind Multicenter Controlled Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04693221
Acronym
OPSTIMVAG
Enrollment
140
Registered
2021-01-05
Start date
2021-04-16
Completion date
2026-12-12
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

epilepsy, vagal nerve stimulation, phase lag index

Brief summary

Vagal nerve stimulation (VNS) is one of the neuromodulation techniques that can be indicated in patients suffering from refractory epilepsies, especially when an open resection has failed or is not indicated. However to date it is not possible to predict which patients will respond and what are the best parameters of stimulation to be set (pulse width, frequency and intensity). It has been shown that responders to VNS have reduced interictal cortical synchronicity on scalp EEG based on phase lag index (PLI), a marker of functional connectivity (Fc) The aim of this study is to test the following hypothesis: setting the parameters of stimulation on the basis of the lowest values of Phase Lag Index (PLI) obtained on scalp EEG with different settings of parameters (as compared with a randomly chosen set of commonly used parameters) will increase the rate of responders to VNS.

Interventions

OTHERChoice of VNS set of parameters based on the lowest PLI

Vagal nerve stimulation according to PLI results.

OTHEREEG

Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female epileptic patients over 12 years of age * Suffering from pharmaco-resistant epilepsy * With newly implanted VNS Aspire SR device * Surgery performed in the previous 6 months * Electrode impedance should be within normal range ( \< 4000 Ohms) * Auto-stim mode working properly * Mean number of seizures of at least (average 4 (mean value) / months during the baseline period) * Patient, parents or legally representatives who have given written informed consent to allow the study data collection and procedures

Exclusion criteria

* Difficulty to read or understand the French language, or inability to understand the information regarding the study * Total patient's IQ below 64 * Subject in exclusion period due to enrolment in another study * Patient with postoperative left vocal cord paralysis * Patient on VNS since more than 6 months

Design outcomes

Primary

MeasureTime frame
Mean number of seizures per monthChange from baseline to 6 months

Secondary

MeasureTime frameDescription
Number of responders in each groupChange from baseline to 6 months
Number of generalized seizuresChange from baseline to 6 months
Number of seizures with fallsChange from baseline to 6 months
Number of seizures with alteration of consciousnessChange from baseline to 6 months
Score of depressionChange from baseline to 6 monthsNDDI-E
Score of anxietyChange from baseline to 6 monthsGAD-7
Score of quality of lifeChange from baseline to 6 monthsQUOLIE 31

Countries

France

Contacts

STUDY_DIRECTORJean-Olivier ARNAUD

Assistance Publique Hôpitaux de Marseille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026